TB-500

TB-500 (Thymosin Beta-4 fragment) is derived from Thymosin Beta-4, a 43-amino-acid protein found in virtually every human cell where it plays a critical role in actin polymerization — the process that enables cells to move, divide, and repair damaged tissue. The specific fragment used in TB-500 is the actin-binding domain responsible for the majority of Thymosin Beta-4's healing activity. First studied in racehorses for accelerating recovery from musculoskeletal injuries, TB-500 attracted attention in human performance communities for its ability to promote healing throughout the body rather than at a single injection site. This systemic distribution distinguishes it from more localized peptides like BPC-157 and makes it particularly useful for widespread inflammation or multiple concurrent injuries. TB-500 is not FDA approved for human use and is currently sold as a research chemical. The majority of controlled evidence comes from animal studies, though extensive anecdotal human use has built a substantial informal evidence base in athletic communities.

TB-500's primary documented benefit is systemic tissue repair. Unlike growth factors that require local administration to be effective, TB-500 is uniquely capable of distributing throughout the body after a single injection, seeking out areas of injury or inflammation. This has been observed in animal models where TB-500 accelerated recovery from cardiac tissue damage, skeletal muscle tears, and skin wounds when administered at sites distant from the injury. Flexibility and range of motion improvement is consistently reported in both animal studies and human anecdotal use. The mechanism appears to involve both muscle fiber repair and reduction of connective tissue stiffness through anti-inflammatory pathways. Hair follicle stimulation is an unexpected but well-documented ancillary effect. TB-500 has been shown to promote hair follicle stem cell differentiation, which has led to its use by some individuals experiencing pattern hair loss — though this remains an off-label application with limited controlled data. Anti-inflammatory effects are well established in animal models, with TB-500 reducing circulating inflammatory cytokines and promoting macrophage-mediated tissue clearance after injury.

TB-500 has a favorable safety profile in animal studies with no documented systemic toxicity at standard doses. In human anecdotal reports, adverse effects are infrequent and mild. Injection site reactions including temporary redness, warmth, or swelling are the most commonly reported effects, particularly early in a protocol. These typically resolve within 24 hours. A transient feeling of fatigue or "heaviness" in the hours following injection has been reported by some users, potentially reflecting an acute immune-modulatory response. This generally resolves without intervention. Because TB-500 promotes angiogenesis — new blood vessel formation — the same theoretical concern about tumor vascularization that applies to BPC-157 exists here. This is not a demonstrated effect in TB-500 research but warrants caution in individuals with a cancer history. Long-term human safety data is entirely absent; all extended-use risk assessments are extrapolated from animal data.

Loading phase (weeks 1–6): 2–2.5 mg administered twice per week via SubQ or IM injection. This higher-frequency loading phase is intended to build systemic peptide levels and drive initial tissue repair. Maintenance phase (ongoing): After the loading phase, many practitioners reduce to 2–2.5 mg once per week or once every two weeks, depending on injury status and therapeutic goals. Administration site: Unlike BPC-157, TB-500 is typically injected anywhere convenient — often the abdomen SubQ — since its systemic distribution means proximity to the injury site is not required for efficacy. Cycle length: Standard protocols run 4–8 weeks of active use followed by an off period of equal length. Some users run continuous low-dose maintenance during high training loads. Stacking timing: When combined with BPC-157, both peptides are typically administered at the same time, though in separate syringes if different injection sites are used.

United States: TB-500 is not FDA approved and not a controlled substance. It is legally purchasable for research purposes under the "research chemical" classification and is widely available from domestic peptide vendors. WADA / Sports: TB-500 is explicitly banned by the World Anti-Doping Agency under the category of "peptide hormones, growth factors, related substances and mimetics." Athletes in tested sports face significant career risk from TB-500 use; detection windows are not fully characterized but testing capabilities for peptides continue to improve. European Union and Australia: Similar gray-area status as BPC-157 in most EU member states. Australia's TGA classifies it as a prescription-only medicine, making unprescribed possession and importation legally problematic.

TB-500 + BPC-157: The canonical healing stack. BPC-157 addresses local angiogenesis and growth factor signaling; TB-500 provides systemic actin-mediated repair. Together they cover more biological territory than either alone. Standard protocol: TB-500 at 2 mg twice weekly + BPC-157 at 250–500 mcg daily. TB-500 + GHK-Cu: Adding copper peptide layers collagen synthesis support onto TB-500's repair activity, making this combination popular for connective tissue injuries and skin recovery. TB-500 alone: For athletes with widespread, systemic inflammation or multiple simultaneous injuries, TB-500 run solo can be preferable to BPC-157 due to its body-wide distribution.

TB-500 — Common Questions